Friday - May 16, 2025
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 12:45 p.m. PT / 3:45 p.m. ET.
Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.
Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
Last Trade: | US$0.57 |
Daily Change: | 0.01 2.55 |
Daily Volume: | 353,523 |
Market Cap: | US$19.020M |
May 13, 2025 March 31, 2025 February 05, 2025 November 14, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load